Drugs / FURESTEM-AD Inj.
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04725136 | Jan 2021 → Jan 2023 | atopic eczema | Kang Stem Biotech Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT01927705 | Sep 2013 → May 2015 | atopic eczema | Kang Stem Biotech Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03269773 | Apr 2018 → Mar 2019 | atopic eczema | Kang Stem Biotech Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-03-21 | Kang Stem Biotech Co., Ltd. | Results [인터뷰] 강스템바이오텍 "글로벌 선두 아토피 줄기세포치료제 임상 3상 전망 밝아" kangstem.com ↗
2018년부터 최근까지 실시된 1차 아토피 피부염 3상 임상시험의 장기추적조사(K0102-E) 데이터를 검토한 결과, 투여 후 3년 시점까지 EASI-50(Eczema Area Severity Index에서 50% 개선) 달성률이 유의미한 수준으로 나타나 단회 투여 후 장기유효성이 확인됐다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-03-21 | Kang Stem Biotech Co., Ltd. | [인터뷰] 강스템바이오텍 "글로벌 선두 아토피 줄기세포치료제 임상 3상 전망 밝아" kangstem.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FURESTEM-AD inj. | “Treatment group: FURESTEM-AD® inj. 5.0 X 107 cells/1.5 mL” NCT03269773 ↗ |
| Modality | Cell therapy | “Further, It has huge possibility as cell therapy products for autoimmune disease.” NCT01927705 ↗ |
| Route | Subcutaneous | “subcutaneous injection” NCT04725136 ↗ |